<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566046</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT: 2006-006518-13</org_study_id>
    <secondary_id>CIC0203/60</secondary_id>
    <secondary_id>LOC/06-06</secondary_id>
    <nct_id>NCT00566046</nct_id>
  </id_info>
  <brief_title>Prevention of Post-traumatic Seizures With Levetiracetam</brief_title>
  <acronym>TRACK</acronym>
  <official_title>Prospective, Randomized, Double-blind Study Assessing the Effects of Levetiracetam Compared to Placebo in the Prevention of Early Epileptic Seizures and Late Epilepsy in Patients With Severe Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-traumatic seizures can appear frequently after a severe traumatic brain injury. Two
      types of seizures are usually identified: early seizures during the week following the trauma
      and late epilepsy afterward. Several antiepileptic drugs are usually used to prevent early
      seizures but no treatment has demonstrated any preventive effect against late epilepsy.
      Levetiracetam is an antiepileptic drug usually used for the treatment of epileptic patients
      and has pharmacologic properties that could also be interesting for the prevention of
      post-traumatic epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision because of to small enrollment
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to early epileptic seizures (&lt;= 8 days) and late epilepsy (from day 9 to 1 year) in patients with severe traumatic brain injury</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of early seizures and of late epilepsy; treatment effects according to the patient's severity, the TDM US Traumatic Coma Data Bank, and the number of regions traumatized; safety of Levetiracetam</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global prognosis (Glasgow Outcome Scale)</measure>
    <time_frame>3 months, 6 months and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Epilepsy, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>Levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months</description>
    <arm_group_label>Levetiracetam</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 18 years old

          2. Patient with severe brain injury defined as follow:

               -  Initial Glasgow Coma score (assessed on the scene of the accident) &lt;= 8 related
                  to the brain injury

               -  Stage 2 to 4 on the TDM US TCDB classification

          3. Initial brain CT scan performed within 48 hours after hospital admission

          4. Either a male or a nonpregnant, non-lactating female who is using adequate
             contraceptive method (a urine laboratory pregnancy test must be negative at baseline)

          5. Written informed consent from the patient's next-of-kin. If no relative is present as
             the time of inclusion, the patients will be included according to the emergency
             procedure

        Exclusion Criteria:

          1. Isolated extradural hematoma

          2. Medical decision to limit patient's care (terminal stage of a cancer, hematological
             malignancies, HIV, etc.)

          3. Current participation in an other protocol or within one month before study entry

          4. Previous treatment with Levetiracetam

          5. Patient's follow-up judged to be difficult by the investigator

          6. Known allergy to either Levetiracetam or products derived from pyrrolidone or one of
             its excipients

          7. Epileptic patient treated or not (except patients treated with benzodiazepines who can
             be included in this protocol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Biraben, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Laviolle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologie - CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology - CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie - CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurochirurgie-CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology - CHU Rennes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurophysiologie Clinique - CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurophysiologie clinique - CHU Lyon (HÃ´pital neurologique)</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beurophysiologie clinique - CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Epileptologie - CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie - CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurochirurgie-Paris Saint Anne</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie - CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Explorations Fonctionnelles Neurologiques - CHU Nantes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie - CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie - CHU Tours Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2007</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

